Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador (VWD)

2 juillet 2013 mis à jour par: Jaime M. Moreno A., M.D., M.S., F.A.C.P., Universidad del Azuay

Hypothesis
a. There are patients with von Willebrand Disease in Cuenca.
Primary question
a. How many women referred with a history of bleeding may have von Willebrand disease?
Secondary
1. Associations between the bleeding score and initial laboratory studies
2. What are the differences on subgroups of enrolled patients with the bleeding score?
Ancillary
1. What is the clinical and socio-economic status of women with von Willebrand Disease in Cuenca?
2. What is the clinical and socio-economic status of patients with Hemophilia in Cuenca?

Aperçu de l'étude

Statut

Complété

Les conditions

Description détaillée

The incidence of hemophilia A is 1 in 10,000 and the one of hemophilia B is 1 in 30,000 live born males. As the most frequent coagulopathy in the world, von Willebrand disease (vWD) can affect 1 in 1000 children of both genders. The prevalence of vWD is 1-2% and it may be as high as 5-15% among women with menorrhagia. So vWD can be present in 1 of every 100 to 500 individuals.

A world survey published that Ecuador, with a population of 14,790,608 people, has 238 patients with hemophilia, 45 people with von Willebrand disease (vWD) and 13 patients with other bleeding disorders including rare factor deficiencies and platelet disorders.

The Ecuadorian census of 2010 indicates that Cuenca district (canton) has 505,585 inhabitants. According to a local reference, Cuenca has no reports of vWD and it has registered 20-40 patients with hemophilia A and B. However Cuenca may host approximately 10,000 people with vWD because it affects both males and females. One plausible explanation for this lag is that the diagnostic suspicions of vWD had not been proven because of the lack of a special coagulation laboratory in Cuenca that would allow professionals to make a positive diagnosis.

This is the first clinical, demographic and socio-economic study of patients registered with hemophilia and of Cuenca women with possible vWD who are referred from dentists and physicians from public and private health centers. The instruments will be validated surveys and screening coagulation studies.

As far as we know Ecuador has not published studies on coagulopathies. Our aim is to initiate a process to eventually reach the goal to offer adequate diagnostic and therapeutic interventions to human victims of these diseases, within a program of service, teaching and research.

Type d'étude

Observationnel

Inscription (Réel)

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

Equateur
- Azuay
  - Cuenca, Azuay, Equateur, 0001
    - UAzuay
  - Cuenca, Azuay, Equateur, 0001
    - Universidad del Azuay (UDA)

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 50 ans (Adulte)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Femelle

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Target population: all women from Cuenca district with a hemorrhage history.

Accessible population: Those women referred from professionals with an initial hemorrhage history, who comply with the inclusion criteria and who sign the informed consert form.

Sample population: First comers referred with a hemorrhage history until fulfilling the projected sample size. This non-probabilistic purposive sample will be used because it has been reported that it could represent the target population.

*2010 Ecuadorian census: 131.163 women ages 18 to 50 years, at Cuenca district.

La description

Inclusion Criteria:

Subjects living at urban and rural parishes from Cuenca district.
Subjects referred from professionals of public and private health services, who have filled the initial hemorrhage survey.
Must be referred women who sign the informed consent form.
Patients who answer the standardized bleeding score questionnaire (BS).
Patients who answer the quality of life questionnaire (SF-12).
Patients who answer the socio-economic survey.
Patients who accept to provide a venous blood sample for the initial laboratory tests.

Exclusion Criteria:

Women with organic or hormonal bleeding etiologies.
Patients taking medicines which may affect the coagulation cascade or the number or function of platelets.
Those women who otherwise do not comply with the inclusion criteria.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Nombre de groupes / cohortes

Cohortes et interventions

Groupe / Cohorte
von Willebrand women Referred women who may have von Willebrand Disease

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats	Description de la mesure	Délai
Bleeding Score (BS) Délai: 1 week	As an adequate bleeding history is fundamental, the Condensed MCMDM-1 Bleeding Questionnaire will be used. Its bleeding score (BS) has a sensitivity of 100%, specificity 87%, positive predictive value 0.2 and negative predictive value 1.0. There was a signifficant difference of BS between the subtypes of vWD: with type 3 >>type 2 >>type 1 vWD (Anova P <0.001). AS the BS is an index of ordinal values, medians and the Mann-Whitney non-parametric ranksum test will be used, to study the bleeding score (BS) differences among subgroups of enrolled women.	1 week

Mesures de résultats secondaires

Mesure des résultats	Description de la mesure	Délai
Associations among BS and female subgroup characteristics and initial laboratory tests. Délai: 1 week	As bleeding may tend to associate in subjects, i.e. epistaxis and menorrhagia, a logistic (log-linear) model will be used. As bleeding can also ocur independently, symptoms will be coded for an adjusted covariate analysis. To study the relationships among the BS and the quantitative laboratory results, the BS will be divided in quintiles, and an adjusted multiple regression model will be used. Likelihood ratios (LR) for values of BS, with a prevalence of 5% and ROC curves will be applied. According to Tosetto et.al. laboratory data will be expressed in categorical and quantitative scales.	1 week

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Universidad del Azuay

Les enquêteurs

Chercheur principal: Jaime M. Moreno A., M.D., M.S., Universidad del Azuay (UAzuay)
Chaise d'étude: Jacinto Guillen G., Eng., M.S., Universidad del Azuay (UAzuay)
Directeur d'études: Rodrigo Cueva M., Econ., M.S., Universidad del Azuay (UAzuay)

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 mars 2013

Achèvement primaire (Réel)

1 juin 2013

Achèvement de l'étude (Réel)

1 juin 2013

Dates d'inscription aux études

Première soumission

30 avril 2012

Première soumission répondant aux critères de contrôle qualité